Medication info
Baratan Tablet 160 mg (Valsartan)

Baratan Tablet 160 mg (Valsartan)

Prescription medicationTabletOral
Ingredient · strength
Valsartan›160mg / 1 tablet
Manufacturer / importer
Hana Pharmaceutical Co., Ltd.
Appearance
Oval film-coated tablet with an orange hue
Packaging
30 tablets/bottle, 100 tablets/bottle
Approval status
Active

MFDS item code 201304289 · Approved 2013.02.07 · Insurance code 657805040

Summary

Main use
Treatment of essential hypertension, improvement of heart failure, and reduction of the risk of death after myocardial infarction
Who takes it
Adults · Children
Adult dose
Essential hypertension Take with water during a meal or between meals. It is recommended that the medication be taken at the same time each day (e.g., in the morning), if possible. Adults: Regardless of sex or race, the recommended dose is 80 mg of valsartan orally once daily. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. In patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg once daily or a diuretic may be added. If further blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg once daily. Older adults (75 years and older): Initiate treatment with 40 mg of this medication once daily. Patients with renal impairment: Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is required. Creatinine clearance 10 ∼ 20 mL/min: Initiate treatment with 40 mg of this medication once daily. Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this medication. Patients with intravascular volume depletion: In patients with intravascular volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), initiate treatment with 40 mg of this medication once daily. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, initiate treatment with 40 mg of this medication once daily; do not exceed 80 mg per day. Do not administer this medication to patients with severe hepatic impairment, cirrhosis, or cholestasis. Heart failure Adults: The recommended starting dose is 40 mg of this medication orally twice daily; the dose may be increased to 80 mg or 160 mg per dose. When administered with a diuretic, consider reducing the diuretic dose. The maximum daily dose is 320 mg, given in divided doses. Triple combination therapy with this medication, an ACE inhibitor, and a beta blocker is not recommended. Reduction of the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours of the onset of myocardial infarction. The recommended starting dose is 20 mg of this medication twice daily. Over the following weeks, increase the dose according to the patient's tolerability to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider dose reduction if hypotension or renal failure occurs. This medication may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytics, acetylsalicylic acid, beta blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. Patients with renal impairment: No dose adjustment is required for creatinine clearance of 10 mL/min or more. However, do not administer this medication to patients with creatinine clearance less than 10 mL/min or patients on dialysis, as there is no experience with its use in these patients. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, it is preferable not to exceed a daily dose of 80 mg. If administering 80 mg or more per day, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medication to patients with severe hepatic impairment, cirrhosis, or cholestasis.
Child dose
Essential hypertension: Children: Safety and efficacy have not been established in children and adolescents under 18 years of age. Children: Safety and efficacy have not been established in children and adolescents under 18 years of age.

Ingredients

Manufacturer
Hana Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of essential hypertension, improvement of heart failure, and reduction of the risk of death after myocardial infarction

  • Essential hypertension
  • heart failure
  • left ventricular dysfunction
  • left ventricular systolic dysfunction
View approved original text

This medication is used to treat essential hypertension, helping to control blood pressure and maintain cardiovascular health. It can also be safely used in heart failure patients who are intolerant to ACE inhibitors, particularly those classified as NYHA stages II to IV. After a myocardial infarction, it is effective in reducing the risk of mortality in patients with left ventricular dysfunction, leading to improved survival rates. Thus, this medication plays an important role in managing hypertension and heart failure and in reducing the risk of mortality after a myocardial infarction.

How to take

Adult dose

Essential hypertension Take with water during a meal or between meals. It is recommended that the medication be taken at the same time each day (e.g., in the morning), if possible. Adults: Regardless of sex or race, the recommended dose is 80 mg of valsartan orally once daily. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. In patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg once daily or a diuretic may be added. If further blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg once daily. Older adults (75 years and older): Initiate treatment with 40 mg of this medication once daily. Patients with renal impairment: Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is required. Creatinine clearance 10 ∼ 20 mL/min: Initiate treatment with 40 mg of this medication once daily. Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this medication. Patients with intravascular volume depletion: In patients with intravascular volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), initiate treatment with 40 mg of this medication once daily. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, initiate treatment with 40 mg of this medication once daily; do not exceed 80 mg per day. Do not administer this medication to patients with severe hepatic impairment, cirrhosis, or cholestasis. Heart failure Adults: The recommended starting dose is 40 mg of this medication orally twice daily; the dose may be increased to 80 mg or 160 mg per dose. When administered with a diuretic, consider reducing the diuretic dose. The maximum daily dose is 320 mg, given in divided doses. Triple combination therapy with this medication, an ACE inhibitor, and a beta blocker is not recommended. Reduction of the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours of the onset of myocardial infarction. The recommended starting dose is 20 mg of this medication twice daily. Over the following weeks, increase the dose according to the patient's tolerability to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider dose reduction if hypotension or renal failure occurs. This medication may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytics, acetylsalicylic acid, beta blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. Patients with renal impairment: No dose adjustment is required for creatinine clearance of 10 mL/min or more. However, do not administer this medication to patients with creatinine clearance less than 10 mL/min or patients on dialysis, as there is no experience with its use in these patients. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, it is preferable not to exceed a daily dose of 80 mg. If administering 80 mg or more per day, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medication to patients with severe hepatic impairment, cirrhosis, or cholestasis.

Child dose

Essential hypertension: Children: Safety and efficacy have not been established in children and adolescents under 18 years of age. Children: Safety and efficacy have not been established in children and adolescents under 18 years of age.

Precautions

This medication, especially when taken in the second and third trimesters of pregnancy, can cause serious harm to the fetus, so it should be discontinued immediately if pregnancy is confirmed. This medication should not be administered to patients with certain conditions. For example, individuals allergic to this medication or its components, pregnant or breastfeeding women, patients with severe liver impairment, patients with hereditary angioedema or a history of angioedema, patients with severe kidney dysfunction, patients with primary hyperaldosteronism, and patients with diabetes or severe kidney impairment should not use it. Elderly patients, those with hyperkalemia, patients with slightly impaired liver function, patients with certain heart conditions, and patients with fluid depletion should exercise special caution when using this medication, as hypotension may appear at the beginning of treatment. Common side effects during the use of this medication may include dizziness, headache, fatigue, cough, and diarrhea, while rare but serious adverse reactions may include angioedema, hepatitis, worsening kidney function, hypoglycemia, and muscle disorders, so any unusual symptoms should be discussed with a healthcare provider immediately. This medication can interact with other drugs, so blood pressure, kidney function, and electrolyte levels should be monitored periodically, especially when used with potassium-sparing diuretics, potassium supplements, non-steroidal anti-inflammatory drugs, and lithium preparations. Pregnant or breastfeeding women are advised not to take this medication, and if it must be used, breastfeeding should be discontinued. Safety and efficacy in pediatric patients under 18 years of age have not been established, so it is advisable not to use this medication in this population. In case of overdose, severe hypotension, consciousness impairment, or shock may occur, and immediate emergency treatment is required, so keep this medication out of reach of children. Finally, this medication has a blood pressure-lowering effect, so caution is needed as dizziness may occur when driving or operating machinery.

Side effects

headache

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture, so it should be stored in a tightly sealed container. Additionally, it should be kept in a cool place below 30 degrees to maintain its efficacy.

Appearance and packaging

Appearance

Oval film-coated tablet with an orange hue

Package unit

30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.